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Abstract
Background: With increased life expectancy for HIV-infected persons, there is concern regarding comorbid depression
because of its common occurrence and association with behaviors that may facilitate HIV transmission. Our objectives were
to estimate the prevalence of current depression among HIV-infected persons receiving care and assess the burden of major
depression, relative to that in the general population.
Methods and Findings: We used data from the Medical Monitoring Project (MMP) and the Behavioral Risk Factors
Surveillance System (BRFSS). The eight-item Patient Health Questionnaire was used to identify depression. To assess the
burden of major depression among HIV-infected persons receiving care, we compared the prevalence of current major
depression between the MMP and BRFSS populations using stratified analyses that simultaneously controlled for gender
and, in turn, each of the potentially confounding demographic factors of age, race/ethnicity, education, and income. Each
unadjusted comparison was summarized as a prevalence ratio (PR), and each of the adjusted comparisons was summarized
as a standardized prevalence ratio (SPR). Among HIV-infected persons receiving care, the prevalence of a current episode of
major depression and other depression, respectively, was 12.4% (95% CI: 11.2, 13.7) and 13.2% (95% CI: 12.0%, 14.4%).
Overall, the PR comparing the prevalence of current major depression between HIV-infected persons receiving care and the
general population was 3.1. When controlling for gender and each of the factors age, race/ethnicity, and education, the SPR
(3.3, 3.0, and 2.9, respectively) was similar to the PR. However, when controlling for gender and annual household income,
the SPR decreased to 1.5.
Conclusions: Depression remains a common comorbidity among HIV-infected persons. The overall excess burden among
HIV-infected persons receiving care is about three-times that among the general population and is associated with
differences in annual household income between the two populations. Relevant efforts are needed to reduce this burden.
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Introduction
With the advent of effective treatment and resultant increases in
life expectancy, HIV infection has become a chronic condition. As
with other chronic medical conditions, HIV infection is often
complicated by comorbid depression [1,2], and there are serious
concerns regarding the adverse impacts of depression on the
quality of life and the course of illness among those living with
HIV. Depressed persons with HIV frequently become non-
adherent with their treatment [3–5], which may lead to higher
HIV viral loads, higher infectiousness, and poorer clinical
outcomes. Some studies have suggested a more rapid progression
to AIDS or an increase in mortality associated with depression
among persons with HIV [6–11]. In addition, depression is
associated with substance abuse [2,12], which may contribute to
reduced quality of life and increased participation in high-risk
behaviors that may transmit HIV.
As the number of persons living with HIV increases, it becomes
increasingly important to understand the extent of the burden of
depression among these individuals, so that appropriate measures
can be taken to alleviate this burden and maximize the
effectiveness of HIV treatment and prevention. Although previous
studies have reported estimates of depression among either
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HIV-infected persons or the general population, few have
concurrently examined depression among both, using the same
measure of depression. Findings from previous studies that have
compared the prevalence of depression between HIV-infected and
uninfected individuals have been mixed, but many of these studies
were limited to groups with specific characteristics (e.g., men who
have sex with men, injection drug users) and involved small
convenience samples [13–22]. A meta-analysis combining data
from 10 such studies found that the prevalence of depression was
higher among HIV-infected persons, compared to uninfected
persons [23]. However, no previous study – to our knowledge –
has compared depression prevalence using large population-based
samples of HIV-infected persons and the general population.
In this report, we address the question of whether HIV infection
is associated with major depression by using population-based data
to estimate the prevalence of current depression among persons
infected with HIV and comparing it to the prevalence of
depression among persons in the general population. We also
assess the roles of major demographic factors in any excess burden
of depression experienced by those with HIV infection.
Methods
We describe the prevalence of depression in a nationally
representative sample of HIV-infected persons receiving care using
population-based data from the Medical Monitoring Project
(MMP) and compare it to the prevalence of depression in a
state-based probability sample of persons in the general population
from the Behavioral Risk Factor Surveillance System (BRFSS).
Medical Monitoring Project (MMP)
MMP is a supplemental HIV surveillance system designed to
produce nationally representative estimates of behavioral and
clinical characteristics of HIV-infected adults receiving medical
care in the United States. MMP methods, including weighting
procedures, have been described in detail elsewhere [24–26].
Briefly, MMP uses a three-stage, probability-proportional-to-size
sampling method. U.S. states and territories were sampled, then
eligible facilities, and finally, eligible individuals. Eligible facilities
were those that provide outpatient HIV care, defined as the
treatment and management of HIV disease, including monitoring
CD4 and HIV viral load tests, or the prescription of antiretroviral
medications. For the 2009 data collection cycle, eligible persons
were HIV-infected adults age 18 years or older receiving medical
care in participating facilities between January and April 2009.
Data were collected through face-to-face interviews and medical
record abstractions from June 2009 through May 2010. All
sampled project areas participated in MMP. Participating areas
included 16 states (California, Delaware, Florida, Georgia, Illinois,
Indiana, Michigan, Mississippi, New Jersey, New York, North
Carolina, Oregon, Pennsylvania, Texas, Virginia, and Washing-
ton), 6 separately-funded large metropolitan areas (Chicago,
Houston, Los Angeles County, New York City, Philadelphia,
and San Francisco) within 5 of the sampled states, and Puerto
Rico. Data from MMP were weighted to produce estimates that
represent all HIV-infected adults receiving care in the U.S.
Ethics Statement
In accordance with the federal human subjects protection
regulations at 45 Code of Federal Regulations 46.101c and 46.102d
and with the Guidelines for Defining Public Health Research and Public
Health Non-Research [27,28], MMP was determined by the National
Center for HIV, Viral Hepatitis, STD and TB Prevention’s Office
of the Associate Director for Science at the Centers for Disease
Control and Prevention (CDC) to be a non-research, public health
surveillance activity used for disease control program or policy
purposes. As such, MMP is not subject to human subjects
regulations, including federal investigational review board (IRB)
review. Nevertheless, participating project areas and facilities
obtained local IRB approval to conduct MMP as required locally,
and individual signed informed consents for participation in MMP
were obtained as required locally. In addition, none of the authors
of this manuscript has had access to any information that would
directly identify individual persons on whom data were collected.
Behavioral Risk Factor Surveillance System (BRFSS)
The BRFSS is a state-based surveillance system operated by
state health departments in collaboration with the CDC. The
objective of the BRFSS is to collect uniform, state-specific data on
preventive health practices and risk behaviors that are linked to
chronic diseases, injuries, and preventable infectious diseases in the
adult population [29,30]. Using a standardized questionnaire,
trained interviewers conduct telephone interviews with individuals
in a probability sample of households with telephones in the non-
institutionalized U.S. adult population. Detailed BRFSS survey
methodology, including weighting procedures, is described else-
where [31].
In brief, the BRFSS questionnaire consists of three parts: core
questions that are asked in all 50 states, the District of Columbia
(D.C.), Puerto Rico, and the U.S. Virgin Islands; local questions
that are added by the states; and optional supplemental modules,
which are a series of questions on specific topics (for example,
adult asthma history, intimate partner violence, and mental
health)[32]. In 2006 and 2008, the state health departments, in
collaboration with CDC and the Center for Mental Health
Services, Substance Abuse and Mental Health Services Adminis-
tration, collaborated on the implementation of the Anxiety and
Depression Module, which consisted of questions about depression
severity and lifetime diagnosis of anxiety and depression (Anxiety
and Depression Module) [32]. During 2006 and 2008 combined, a
total of 45 states, D.C., Puerto Rico, and the U.S. Virgin Islands
implemented this module (29 states, D.C., Puerto Rico, and U.S.
Virgin Islands in 2006; 16 states in 2008). For the 9 states that
implemented the module during both 2006 and 2008 (Hawaii,
Kansas, Louisiana, Maine, Mississippi, Nebraska, North Dakota,
Vermont, and Washington), only the 2008 data were included in
this analysis.
Eight-item patient health questionnaire depression scale
(PHQ-8)
The PHQ-8 consists of eight of the nine criteria on which the
Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-
IV) diagnosis of depressive disorders is based [33]. The ninth
question in the DSM-IV assesses suicidal or self-injurious ideation
and was omitted because not all interviewers were trained mental
health providers. Research indicates that the deletion of this
question has only a minor effect on scoring because active
thoughts of self-harm are uncommon in the general population
[34] and in primary care settings [35,36]. The PHQ-8 has been
shown to be comparable to the PHQ-9 [37,38], which includes all
nine DSM-IV criteria for depressive disorders and has demon-
strated good psychometric properties in detecting major depres-
sion in non-psychiatric care settings. In a published review of
validation studies, the PHQ-9 had reported values for sensitivity of
0.77 to 0.88, specificity of 0.88 to 0.94, internal reliability
(Cronbach a) of 0.86 to 0.89, and external reliability (test-retest)
of 0.84 in detecting major depressive disorders in a variety of
care settings and patient populations [37]. Both the PHQ-8 and
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PHQ-9 have been used in clinical [39–44] and general population
settings [45–48], and both have been used in self-administered
[42–44,48] and telephone-administered modes [45,49]. The
PHQ-9 has also been shown to be effective for detecting depressive
symptoms in various racial and ethnic groups [44,46,49,50].
For both MMP and BRFSS, participants were considered to
have current major depression if, for ‘‘more than half the days’’ in
the preceding two weeks, they met at least five of the eight criteria,
including at least one of the following: 1) "little interest or pleasure
in doing things" or 2) "feeling down, depressed, or hopeless."
Participants were considered to have "other depression" if they
experienced between two to four depressive symptoms for ‘‘more
than half the days’’ in the preceding two weeks, with at least one
being depressed mood or anhedonia. The PHQ-8 classification
"other depression" comprises the DSM-IV categories of dysthymia
and depressive disorder, not otherwise specified, which includes
minor or subthreshold depression [33]. For the comparison of
depression prevalence between MMP and BRFSS, we conducted
standardized comparisons for major depression, which is more
severe and disabling than other forms of depression.
Analytical methods
For each of the two surveys, the distributions of demographic
characteristics were first summarized with unweighted counts and
weighted percentages with 95% confidence intervals (CI). Factors
common to both surveillance systems were gender, age at the time
of interview, race/ethnicity, and highest level of education
attained. We additionally included time since HIV diagnosis and
sexual orientation, which were only assessed in MMP. Next, the
weighted prevalence and 95% CI of major, other, and any current
depression among MMP participants were estimated overall and
among the categories of demographic factors, analogous to
published results for BRFSS in 2006 and 2008 [51,52].
Comparisons between categories were made using the modified
Rao-Scott x2 Test [53].
To understand the degree to which the burden of major
depression among HIV-infected adults receiving care is elevated
compared to a probability sample drawn from the general U.S.
population, we conducted stratified analyses that simultaneously
controlled for gender and, in turn, one of the potentially
confounding demographic factors of age, race/ethnicity, educa-
tion, and income. The latter demographic factors were considered
within gender categories because of the substantial differences in
gender distribution between the two surveillance projects and the
established relationship between gender and depression [2].
Within each stratum, we calculated the weighted prevalence and
associated standard error (SE) of each depression outcome for both
MMP and BRFSS. The weighted prevalences were compared
between the two systems with prevalence ratios (PR). These
stratum-specific estimates were then summarized with standard-
ized prevalence ratios (SPRs) and their 95% CIs, utilizing the
weighted prevalences and their SEs [54]. Thus, for each
depression outcome, 4 SPRs were computed as the combinations
of gender with age, race/ethnicity, education, or income.
Together, these provided different perspectives of the excess in
depression seen among HIV patients receiving care. This
approach is an extension of the indirect method for calculating
the age-adjusted standardized mortality ratios, in which the
observed mortality rate in a population of interest is compared
with an expected one derived from the age-specific mortality rates
of a standard population [55]. With MMP as the population of
interest and BRFSS as the standard population, factors known to
be associated with depression were identified as key elements for
standardization in our comparison, as explained above. To
account for the complex survey designs, weighted analyses were
conducted using PROC SURVEYFREQ in SAS 9.3 (SAS
Institute, Cary, NC) for MMP data and SAS callable SUDAAN
(RTI International, Research Triangle Park, NC) for BRFSS data.
SPR calculations were performed in Microsoft Excel 2010
(Microsoft Corporation, Redmond, WA).
Although a high prevalence of depression has been observed
among groups with increased risk for HIV, like men who have sex
with men and injection drug users [12,56–60], data were not
available to adjust for these characteristics in our comparison of
depression prevalence among MMP and BRFSS populations.
However, we were able to determine the prevalence of depression
among persons in the general population who reported one or
more HIV risk behaviors, which might indicate that these
individuals have an increased risk for HIV infection. To determine
the presence of HIV risk behaviors, we analyzed responses to the
following question, which was first included in the 2008 BRFSS
core survey and was only directed to participants younger than 65
years of age: ‘‘I’m going to read you a list. When I’m done, please
tell me if any of the situations apply to you. You do not need to tell
me which one: 1) You have used intravenous drugs in the past
year, 2) You have been treated for a sexually transmitted or
venereal disease in the past year, 3) You have given or received
money or drugs in exchange for sex in the past year, 4) You had
anal sex without a condom in the past year. Do any of these
situations apply to you?’’ [61]. The prevalence of major depression
by gender and the presence of one or more HIV risk behaviors
were calculated and summarized using unweighted counts and
weighted percentages with 95% CI. Using the two-proportion Z
test, statistical comparisons were made between the prevalence of
major depression among persons in the general population with
self-reported HIV risk behaviors and the prevalence of major
depression in each of two other groups – persons in the general
population who did not report such behaviors (BRFSS) and HIV-
infected persons receiving care (MMP). These comparisons were
made within gender categories to account for any gender-related
difference in depression prevalence.
Results
Demographics
Among 4,217 MMP participants included in this analysis, 4,168
(98.7% of weighted sample) completed the PHQ-8 and comprised
our analytic sample from MMP. As shown in Table 1, the largest
proportions of the respondents who completed the PHQ-8 were
male (71.2%), African-American (41.3%), and diagnosed with
HIV at least 10 years previously (53.9%). A large proportion
(59.1%) was age 45 or older, and only 14.2% was less than age 35.
Although the largest proportion (49.3%) self-reported being
heterosexual or straight, a considerable proportion (40.9%)
reported being homosexual. The level of education was less than
high school for 22.5%, and the annual household income was less
than $10,000 for 34.5%.
Among 267,584 BRFSS participants who were offered partic-
ipation in the Anxiety and Depression Module in 2006 or 2008,
235,067 (88.7% of weighted sample) completed the PHQ-8 and
comprised the analytic sample from BRFSS. In contrast to the
HIV-infected population receiving care, the largest proportion of
the general population sample from BRFSS was female (51.4%)
and white (70.5%). Less than half (48.5%) of the general
population sample was age 45 or older, and a substantial
proportion (31.3%) was younger than age 35. The level of
education was less than high school for only 10.8%, and the
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annual household income was less than $10,000 for only 4.8% of
the general population sample.
Depression prevalence
Depression was common among HIV-infected persons receiv-
ing care, with PHQ-8 responses indicating an estimated 12.4%
(95% CI: 11.2%, 13.7%) prevalence of current major depression
and 13.2% (95% CI: 12.0%, 14.4%) of other depression, yielding
25.6% (95% CI: 23.8%, 27.4%) with any current depression.
Statistically significant heterogeneity in the prevalence of major
depression was seen by levels of gender (p,0.0001), age
(p = 0.005), education (p = 0.001) and annual income
(p,0.0001). Major depression was most common among female
(17.0%) and transgender (17.5%) participants and among those
between 35 and 44 years old (15%), with less than a high school
education (16.2%), or with an annual income less than $10,000
(16.5%)(Table 2). No association was observed between major
depression and race/ethnicity, time since HIV diagnosis, or sexual
orientation.
Based on BRFSS data, the prevalence of depression among
general population adults was estimated to be 4.1% (95% CI:
Table 1. Self-reported characteristics of HIV-infected adults receiving medical care and general population adults in the United
States who completed the Eight-item Patient Health Questionnaire depression scale — Medical Monitoring Project (MMP) 2009
and Behavioral Risk Factor Surveillance System (BRFSS), 2006 and 2008.
MMP BRFSS
n sample wgt. col % (95% CI) n sample wgt. col % (95% CI)
Overall 4,168 235,067
Gender
Male 2,981 71.2 (68.1, 74.4) 89,842 48.6 (48.2, 49.1)
Female 1,123 27.1 (24.0, 30.3) 145,225 51.4 (50.9, 51.8)
Transgender* 64 1.6 (1.1, 2.1) ___ ___
Age at interview
18–24 107 2.5 (1.8, 3.3) 9,944 12.6 (12.2, 13.0)
25–34 495 11.7 (10.4, 13.0) 27,086 18.7 (18.3, 19.1)
35–44 1,112 26.7 (25.3, 28.0) 39,440 20.2 (19.9, 20.6)
45–54 1,622 39.0 (37.2, 40.7) 49,623 19.0 (18.7, 19.3)
$ 55 833 20.1 (18.6, 21.6) 107,265 29.5 (29.2, 29.8)
Race/ethnicity{
Black/African American 1,718 41.3 (33.1, 49.6) 17,604 8.5 (8.3, 8.8)
Hispanic or Latino 874 19.2 (14.2, 24.2) 18,391 14.8 (14.4, 15.2)
White 1,383 34.7 (28.2, 41.3) 183,563 70.5 (70.1, 71.0)
Other 193 4.7 (3.7, 5.6) 13,528 6.1 (5.9, 6.4)
Education
, High school (HS) 969 22.5 (19.9, 25.0) 21,463 10.8 (10.5, 11.1)
HS diploma or equivalent 1,149 26.8 (24.1, 29.6) 68,250 27.9 (27.5, 28.3)
. HS 2,050 50.7 (45.9, 55.5) 145,020 61.4 (60.9, 61.8)
Annual Income
$0 to $9,999 1,458 34.5 (30.6, 38.3) 10,883 4.8 (4.6, 5.1)
$10,000 to $19,999 1,165 29.4 (27.6, 31.2) 26,540 11.2 (10.9, 11.5)
$20,000 to $49,999 881 23.0 (20.3, 25.8) 79,253 34.9 (34.5, 35.4)
$50,000+ 491 13.1 (10.5, 15.6) 91,230 49.0 (48.5, 49.5)
Time since HIV diagnosis
0 – 5 years 937 23.1 (21.2, 25.1) ___ ___
5 – 10 years 966 23.0 (21.5, 24.5) ___ ___
10+ years 2,261 53.9 (51.4, 56.3) ___ ___
Sexual orientation
Homosexual, gay, or lesbian 1,679 40.9 (36.3, 45.6) ___ ___
Bisexual 342 8.2 (7.2, 9.2) ___ ___
Heterosexual or straight 2,080 49.3 (44.4, 54.3) ___ ___
Other 57 1.6 (0.9, 2.3) ___ ___
*Male-to-female or female-to-male; {mutually exclusive race/ethnicity categories.
wgt. col% = weighted column %; 95% CI = 95% confidence intervals.
doi:10.1371/journal.pone.0092842.t001
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3.9%, 4.2%) for current major depression and 5.1% (95% CI:
4.9%, 5.3%) for current other depression, yielding 9.1% (95% CI:
8.9%, 9.4%) for any current depression (Table S1), and variations
across categories of gender, age, education, and annual income
were similar to those seen among HIV-infected persons receiving
care, as demonstrated by MMP data. In contrast to HIV-infected
persons receiving care, however, statistically significant differences
were seen across racial/ethnic groups, with a higher prevalence of
major depression seen among non-Hispanic blacks (5.0%),
Hispanics (4.7%), or non-Hispanic persons of other races (5.1%)
than among white, non-Hispanic persons (3.7%) in the general
population.
Comparison of depression prevalence (MMP and BRFSS)
Overall, the unadjusted prevalence ratio of current major
depression among HIV-infected adults receiving care, compared
to those in the general population, was 3.1. Similar results were
observed when comparing the prevalence of current major
depression across the two populations by gender, with the
prevalence ratio being 3.2 for men and 3.5 for women.
Table 2. Weighted percentage of HIV-infected adults receiving medical care in the United States who met criteria for current
depression*, by type of depression and selected self-reported characteristics — Medical Monitoring Project, 2009.
Major depression Other depression Any current depression
n wgt. row % (95% CI) n wgt. row % (95% CI) n wgt. row % (95% CI)
Total 506 12.4 (11.2, 13.7) 535 13.2 (12.0, 14.4) 1,041 25.6 (23.8, 27.4)
Gender
Male 305 10.6 (9.2, 12.0) 367 12.7 (11.2, 14.2) 672 23.3 (21.4, 25.3)
Female 189 17.0 (14.6, 19.3) 160 14.4 (12.4, 16.3) 349 31.3 (28.2, 34.4)
Transgender{ 12 17.5 (6.7, 28.4) 8 11.7 (3.7, 19.8) 20 29.3 (16.7, 39.9)
Age at interview
18–24 13 12.1 (3.9, 20.2) 11 12.0 (4.7, 19.4) 24 24.1 (12.8, 35.3)
25–34 71 13.8 (10.3, 17.3) 66 13.7 (10.4, 17.0) 137 27.4 (23.1, 31.8)
35–44 151 15.0 (12.8, 17.2) 146 13.3 (11.3, 15.2) 297 28.3 (25.0, 31.6)
45–54 202 12.4 (10.3, 14.5) 216 14.0 (12.2, 15.9) 418 26.4 (23.8, 29.1)
$ 55 69 8.4 (6.5, 10.3) 96 11.1 (8.8, 13,4) 165 19.5 (16.7, 22.2)
Race/ethnicity
Black/African American 200 11.7 (9.8, 13.6) 252 15.0 (13.0, 17.1) 452 26.7 (24.0, 29.5)
Hispanic or Latino 118 13.8 (11.0, 16.5) 111 12.8 (10.4, 15.1) 229 26.5 (23.1, 29.9)
White 170 13.0 (11.0, 15.0) 145 11.0 (9.2, 12.7) 315 24.0 (21.3, 26.7)
Other 18 9.6 (6.4, 12.8) 27 14.3 (7.4, 21.2) 45 23.9 (16.8, 31.1)
Education
, High school (HS) 153 16.2 (13.8, 18.7) 155 15.8 (13.4, 18.1) 308 32.0 (28.8, 35.1)
HS diploma or equivalent 138 11.8 (9.7, 14.0) 167 15.3 (13.4, 17.3) 305 27.2 (24.6, 29.7)
. HS 214 11.0 (9.4, 12.7) 213 10.8 (9.1, 12.5) 427 21.9 (19.4, 24.4)
Annual Income
$0 to $9,999 239 16.5 (14.1, 18.9) 232 17.0 (15.0, 19.0) 471 33.5 (30.4, 36.6)
$10,000 to $19,999 137 12.6 (10.1, 15.1) 150 12.5 (10.0, 15.0) 287 25.1 (21.2, 29.0)
$20,000 to $49,999 79 9.4 (7.4, 11.3) 98 11.7 (9.6, 13.8) 177 21.1 (18.0, 24.1)
$50,000+ 20 4.0 (2.5, 5.6) 26 5.8 (4.3, 7.3) 46 9.8 (7.7, 11.9)
Time since HIV diagnosis
0 – 5 years 117 11.9 (8.7, 15.1) 124 13.4 (10.6, 16.2) 241 25.3 (20.3, 30.3)
5 – 10 years 113 11.9 (9.5, 14.2) 136 14.9 (12.7, 17.1) 249 26.8 (23.9, 29.7)
10+ years 276 12.9 (11.2, 14.7) 274 12.3 (10.6, 13.9) 550 25.2 (22.7, 27.8)
Sexual orientation
Homosexual, gay, or lesbian 182 11.2 (9.6, 12.9) 187 11.6 (9.8, 13.4) 369 22.8 (20.2, 25.5)
Bisexual 44 14.2 (10.0, 18.5) 55 16.5 (12.2, 20.7) 99 30.7 (23.9, 37.5)
Heterosexual or straight 267 13.0 (11.2, 14.7) 286 14.0 (12.5, 15.6) 553 27.0 (24.6, 29.3)
Other 11 18.1 (8.8, 27.3) 5 8.2 (0.2, 16.3) 16 26.3 (15.2, 37.4)
*Based on 4,168 persons who completed the Eight-item Patient Health Questionnaire (PHQ-8) depression scale; {Male-to-female or female-to-male.
wgt. row% = weighted row %; 95% CI = 95% confidence intervals.
Responses to the PHQ-8 were used to define ‘‘Major depression’’ and ‘‘Other depression’’ according to criteria from the Diagnostic and Statistical Manual of Mental
Disorders, 4 th Edition. Any depression is the presence of either major depression or other depression.
doi:10.1371/journal.pone.0092842.t002
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Stratified comparisons of current major depression between
MMP and BRFSS are presented in Table 3. Standardized
prevalence ratios (SPR) that controlled for gender and each of
the factors age, race/ethnicity, and education, indicated a
prevalence of current major depression in MMP that was
approximately three-fold (3.3, 3.0, and 2.9, respectively) that seen
in BRFSS. When controlling for gender and annual income, the
estimated excess burden of major depression was lower, with an
SPR of 1.5.
These relationships were similar for the two additional
depression outcomes considered. For current other depression,
the SPR controlling for gender with age was 2.9 (95% CI: 2.6, 3.2),
with race/ethnicity 2.1 (95% CI: 1.9, 2.4), with education 2.4
(95% CI: 2.2, 2.6), with income 1.6 (95% CI: 1.4, 1.8).
Considering the outcome of any current depression, the SPR
controlling for gender with age was 3.1 (95% CI: 2.9, 3.3), with
race/ethnicity 2.5 (95% CI: 2.3, 2.7), with education 2.6 (95% CI:
2.4, 2.8), with income 1.5 (95% CI: 1.4, 1.7).
Sub-analysis of depression prevalence and HIV risk
behaviors
Among 61,128 participants of the 2008 BRFSS survey ,65
years of age who responded to the question about HIV risk
behaviors, 1,475 (3.4% of weighted sample) reported they had one
or more such behaviors in the preceding year. For male
respondents, the prevalence of current major depression was
6.1% (95% CI: 3.9, 9.5) among 637 who reported having one or
more HIV risk behaviors and 3.0% (95% CI: 2.6, 3.4) among
23,142 who did not report having such behaviors (p = 0.03). For
female respondents, the prevalence of current major depression
was 10.6% (95% CI: 7.6, 14.5) among 838 who reported having
one or more HIV risk behaviors and 4.9% (95% CI: 4.4, 5.3)
among 36,511 who did not report having such behaviors (p,0.01).
Men ,65 years of age in the general population who reported
one or more HIV risk behaviors had a lower prevalence of current
major depression compared to men ,65 years of age receiving
care for HIV infection (6.1% vs. 10.6%, p,0.01). Women ,65
years of age in the general population who reported one or more
HIV risk behaviors had a lower prevalence of current major
depression compared to women ,65 years of age receiving care
for HIV infection (10.6% vs. 17.0%, p,0.01).
Discussion
In this report we present the first nationally representative data
available on depression among HIV-infected adults receiving care
in the U.S. since the HIV Cost and Services Utilization Study
(HCSUS) was conducted during 1994–2000 [62], and the largest
analysis of such data to date. Based on data from the 2009 MMP
cycle, among HIV-infected persons receiving outpatient care in
the U.S., more than a quarter – or over 100,000 – had symptoms
Table 3. Relative and standardized prevalence of major depression by gender and four demographic characteristics — Medical




MMP BRFSS MMP BRFSS
wgt. % (SE) wgt. % (SE) PR wgt. % (SE) wgt. % (SE) PR SPR (95% CI)
Age at interview 3.33 (2.97, 3.74)
18–24 8.8 (5.4) 2.5 (0.4) 3.61 18.8 (7.0) 5.1 (0.5) 3.70
25–34 10.1 (2.5) 3.7 (0.4) 2.75 21.1 (3.7) 4.7 (0.3) 4.46
35–44 13.1 (1.7) 3.3 (0.3) 4.02 19.2 (2.2) 5.4 (0.3) 3.55
45–54 11.5 (1.2) 4.0 (0.2) 2.87 15.3 (2.1) 5.8 (0.2) 2.64
$ 55 6.4 (1.2) 1.7 (0.2) 3.73 12.8 (2.4) 2.4 (0.1) 5.45
Race/ethnicity 3.02 (2.68, 3.41)
Black/African American 9.3 (1.3) 3.8 (0.4) 2.46 14.9 (1.5) 6.1 (0.4) 2.45
Hispanic or Latino 9.7 (1.4) 3.7 (0.5) 2.61 24.6 (3.4) 5.7 (0.4) 4.29
White 12.5 (1.1) 3.0 (0.1) 4.19 16.0 (2.5) 4.4 (0.1) 3.63
Other 7.0 (1.6) 4.4 (0.6) 1.57 22.2 (6.9) 6.0 (0.5) 3.72
Education 2.88 (2.58, 3.21)
, High school (HS) 13.1 (1.8) 6.3 (0.6) 2.08 19.9 (2.1) 10.0 (0.6) 1.98
HS diploma or equivalent 11.3 (1.3) 4.0 (0.3) 2.85 13.4 (1.8) 5.8 (0.2) 2.29
. HS 9.5 (0.9) 2.3 (0.1) 4.04 16.9 (2.3) 3.5 (0.1) 4.78
Annual income 1.45 (1.28, 1.65)
$0 to $9,999 13.5 (1.4) 11.8 (1.4) 1.15 21.0 (1.9) 16.0 (0.9) 1.31
$10,000 to $19,999 11.7 (1.4) 8.0 (0.6) 1.46 15.2 (2.1) 10.6 (0.5) 1.43
$20,000 to $49,999 9.5 (1.1) 3.8 (0.3) 2.52 8.7 (2.6) 5.0 (0.2) 1.75
$50,000+ 4.5 (0.9) 1.4 (0.1) 3.14 0.6 (0.6) 2.0 (0.10 0.30
wgt. % = weighted %; SE = standard error; PR = prevalence ratio (unadjusted); SPR = standardized prevalence ratio; 95% CI = 95% confidence intervals.
Responses to the Eight-item Patient Health Questionnaire were used to define ‘‘major depression’’ according to criteria from the Diagnostic and Statistical Manual of
Mental Disorders, 4th Edition.
doi:10.1371/journal.pone.0092842.t003
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of any depression, including about 12% – or over 50,000 – with
symptoms that were consistent with a current major depressive
episode. Given the chronic and episodic nature of depression, the
full burden of this condition over time is likely greater than is
demonstrated by our estimates of current depression. Although not
directly comparable, the one-year prevalence of major depression
estimated by HCSUS (22%) was nearly twice as high as our MMP
estimate for current major depression [62].
The high burden of depression among HIV-infected persons is
more apparent when compared with that among the general
population. Based on our data, the prevalence of current major
depression among HIV-infected persons receiving outpatient care
was over three times that seen in a general population sample from
BRFSS. Further, similar excesses in major depression prevalence
were seen by gender, and the higher relative prevalences among
HIV-infected persons appeared to be primarily related to lower
annual household income. Although the prevalence ratio for
current major depression changed somewhat when the two
populations were standardized to account for differences in gender
and either age (SPR = 3.3), race/ethnicity (SPR = 3.0), or educa-
tional attainment (SPR = 2.9), it changed dramatically when
standardized for gender and annual household income level
(SPR = 1.5). Lower socioeconomic status, particularly poverty, is
known to be associated with HIV infection and with depression
[63–67], and the nature of these relationships is likely complicated.
For example, income may be an indicator of the degree of access
to health care resources, which may affect HIV-related knowledge
and behaviors and the general health status of individuals. Poor
health status – manifesting as chronic illnesses or as conditions that
might lead to such illnesses – may contribute to the risk for
depression, and depression, in turn, may contribute to poorer
health and lower socioeconomic status [65,68,69].
In comparing the depression prevalence between HIV-infected
persons and the general population, it was important to recognize
the differences in demographics between these two populations
and the need to account for them, because certain demographic
groups in which depression prevalence is known to be higher
(persons with low socioeconomic status) or lower (men) are over-
represented among HIV-infected persons [63,70]. The SPRs
calculated from MMP and BRFSS data provided a useful way to
perform such a comparison and to assess whether there was an
excess burden of major depression among HIV-infected persons
receiving care beyond what would be expected based on their
demographic composition alone. Based on our findings, socioeco-
nomic factors, particularly annual household income, were
important confounding factors that should be taken into account
in such comparisons.
Although lower income accounted for much of the excess major
depression among HIV patients, it did not fully account for it. An
excess in depression prevalence remained, whether the prevalence
ratio was adjusted for race/ethnicity, education, or household
income. When standardized for annual household income, there
was approximately a 50% excess depression among HIV patients.
This finding is consistent with that from some previous studies,
including a meta-analysis that reported that the odds of recent
depression (within the past 1 to 6 months) were 2 times as great
among persons with HIV, compared to those without HIV, and
that sexual orientation did not account for the excess in major
depression among those with HIV [23]. Further, our analysis of
available data from BRFSS indicated that although the prevalence
of current major depression was estimated to be higher among
those with $1 risk factors for HIV than among those without such
risk factors, it was still lower than the observed prevalence among
MMP participants (who were living with HIV). Taken together,
these observations suggest that, although some excess in major
depression may be explained by circumstances related to risks for
HIV acquisition, factors associated with having HIV – as a chronic
illness – are also associated with higher prevalence of major
depression.
It is notable that our estimate of the prevalence of current major
depression among HIV patients is comparable to estimates of
current depression associated with common chronic medical
conditions such as diabetes mellitus (DM)(6.3%–13.3%, PHQ-8
algorithm for current major depression[71]) and cardiovascular
disease (15.8% among persons $45 years, PHQ-8 score $10
[72]). The association between chronic medical illnesses and
depression has been well-recognized, but the reasons for this are
not fully understood. Multiple contributing factors – psychosocial,
behavioral, and biological – are likely involved, and cross-sectional
studies cannot establish their temporal relationships. Factors that
might lead to comorbid depression include physical symptoms,
side effects of medications, social stigma associated with the illness,
and social isolation due to symptom severity or disability
[3,59,68,73]. Depression, in turn, might increase the risk for
development of a chronic illness, or exacerbate an underlying
chronic illness through its impact on behaviors (e.g., substance
abuse, treatment non-adherence)[3,68,74,75]. Immunologic and
endocrinologic changes that are observed more commonly in
people with than without depression might increase the risk for
some chronic medical conditions or lead to poorer outcomes
among those with a chronic medical condition [76–79]. Therefore,
the importance of screening for and treatment of depression is
increasingly being recognized, especially in the context of HIV or
other chronic medical conditions [80–85].
Some limitations should be considered in interpreting the results
in this report. Because MMP participants were all sampled
through medical care providers, our results are representative of
persons receiving care for HIV infection, but not all HIV-infected
persons. It is not clear how the exclusion of those not receiving
care for HIV would affect the prevalence estimates for depression,
because depression might manifest as either increased care seeking
[86] or not engaging in care [74,87]. The use of the PHQ-8 might
have led to the overestimation or underestimation of the
prevalence of major depression. Overestimation might result from
the fact that the PHQ-8 is not equivalent to a full diagnostic
interview, and, therefore, might include depressive episodes caused
by underlying mental or physical illnesses other than major
depression [33]. The focus on identifying current (past 2 weeks)
depression, however, might have led to underestimating the
prevalence of major depression. Although helpful in minimizing
recall bias, such a short time frame might not allow the detection
of depression among individuals whose symptoms remit and recur
episodically over time. Underestimation of the prevalence of
depression might also result from the fact that individuals who
have received care for their HIV infection might have received
care that was effective in controlling their depression as well.
Several limitations might have affected the PRs and SPRs in our
comparisons between MMP and BRFSS data. We were not able
to standardize specifically for sexual orientation or substance abuse
in our comparisons, which might have led to an overestimation of
the PRs and SPRs. Nevertheless, our finding regarding major
depression among general population adults with $1 HIV risk
behaviors suggested that factors related to such behaviors did not
fully account for the higher burden of major depression seen
among HIV-infected persons receiving care. The difference in
modes of administration between MMP (in-person) and BRFSS
(telephone), in addition, might have contributed to underestima-
tion of the PRs and SPRs. In a previous comparison of data from
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two national surveys, the depression prevalence estimate measured
by the PHQ-8 was found to be higher with telephone adminis-
tration than with in-person administration [88].
Limitations with BRFSS data are related to two main issues.
First, the increase in the number households with cellular
telephones only and in telephone number portability continue to
decrease BRFSS response rates, reducing the precision of state
estimates and potentially introducing bias [89]. Second, because
not all states participated, estimates might not be generalizable to
the entire U.S. adult population. Furthermore, due to the cross-
sectional design of MMP and BRFSS, we were not able to make
inferences regarding causality or temporality.
Despite the limitations of our analysis, it is clear that depression
is an important comorbidity among HIV patients. Based on our
results, about one in eight patients in care for HIV had current
symptoms consistent with major depression, and about one in four
had current symptoms of any type of depression. Using
representative data sources for HIV-infected persons in care and
the general population, the unadjusted prevalence of major
depression among those in care for HIV is over three times that
among the general population. This large relative difference in
depression prevalence appeared to be primarily related to
differences in annual household income. However, even after
standardizing for income level, a smaller but important residual
excess in depression burden remained, suggesting there might be
additional factors contributing to this excess burden among HIV-
infected persons who are receiving care.
Our findings also indicate that despite the availability of
effective treatment for depression, many HIV-infected persons had
symptoms consistent with major depression, raising concern about
access to care and quality of care. Although some clinical
guidelines exist for depression screening that are specific to HIV
care settings [81,84], it is not clear how widely adopted they are
among HIV care providers, but there is evidence that many
persons who are in care for HIV infection have depression that is
not recognized and treated by their HIV care providers [90,91].
Given the complexity of HIV treatment, HIV care providers may
need training on issues related to the clinical management of
depression in their patients, who may be taking multiple
medications with various side effects and the potential for drug
interactions. In addition, models for incorporating the manage-
ment of depression within the HIV medical home have been
developed and may be an effective approach to consider in
ensuring appropriate care for HIV patients with depression in
settings where access to mental health care is limited [92]. As
interest grows in improving HIV prevention through antiretroviral
treatment, it becomes increasingly important to recognize the role
of comorbid depression in HIV infection and to closely integrate
the screening for and treatment of depression with routine clinical
management of HIV. Furthermore, because not all HIV-infected
persons are in care, considerations should also be given to
incorporating depression screening and treatment into HIV
prevention programs, particularly those that address issues among
those who are socioeconomically disadvantaged [93,94]. Because
of the potential detrimental effect of depression on HIV
prevention and on the clinical outcomes of HIV-infected persons,
effective treatment and follow-up over time are essential to the
effective management of this chronic and disabling condition,
which continues to affect many persons living with HIV in the
U.S.
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